

# Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025

2025-10-31

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced upcoming presentations, including three Late Breaking Science presentations related to MAPLE-HCM (*Metoprolol vs Aficamten* in Patients with LVOT Obstruction on Exercise Capacity in HCM), at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions on November 7, 2025, and at the American Heart Association Scientific Sessions 2025 taking place November 7-10, 2025, both in New Orleans, LA.

## Hypertrophic Cardiomyopathy Medical Society Scientific Sessions

### Late Breaking Science Presentation

**Title:** Effect of *Aficamten vs Metoprolol* on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy

**Presenter:** Michael E. Nassif, M.D., University of Missouri Kansas City Healthcare Institute for Innovations in Quality and Saint Luke's Mid America Heart Institute

**Date:** November 7, 2025

**Session Title:** Featured Science: Hypertrophic Cardiomyopathy Medical Society

**Session Time:** 6:00 PM – 6:35 PM CT

**Presentation Time:** 6:16 PM – 6:22 PM CT

**Location:** R01

### Oral Presentation

**Title:** Long-term Impact of *Aficamten* on Patient-Reported Outcome Measures in Obstructive Hypertrophic Cardiomyopathy: Results From FOREST-HCM

**Presenter:** Shepard D. Weiner, M.D., Columbia University Irving Medical Center

**Date:** November 7, 2025

**Session Title:** Hypertrophic Cardiomyopathy Medical Society Oral Abstracts

**Session Time:** 2:40 PM – 3:30 PM CT  
**Presentation Time:** 2:50 PM – 2:58 PM CT  
**Location:** R02-R03

### Poster Presentation

**Title:** Outcomes Following Septal Myectomy in Young Patients with Obstructive Hypertrophic Cardiomyopathy  
**Presenter:** Daniel Kamna, D.O., Oregon Health & Science University  
**Date:** November 7, 2025  
**Session Title:** Hypertrophic Cardiomyopathy Medical Society Posters  
**Session Time:** 6:30 PM – 7:30 PM CT  
**Location:** R04-R05 Posters

### American Heart Association Scientific Sessions 2025

#### Late Breaking Science Presentations

**Title:** Clinical Responses to *Aficamten* Monotherapy Compared with *Metoprolol* Monotherapy for Obstructive Hypertrophic Cardiomyopathy Outcomes and Disease Burden: MAPLE-HCM Responder Analysis  
**Presenter:** Andrew Wang, M.D., Duke University Medical Center  
**Date:** November 8, 2025  
**Session Title:** From Madrid to Mardi Gras: Heart Failure Trials on Parade  
**Session Time:** 1:30 PM – 2:45 PM CT  
**Presentation Time:** 1:59 PM – 2:07 PM CT  
**Location:** 211-213

**Title:** Effect of *Aficamten* versus *Metoprolol* Monotherapy on Biomarkers in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Trial  
**Presenter:** Neal K. Lakdawala, M.D., Brigham and Women's Hospital, Harvard Medical School  
**Date:** November 9, 2025  
**Session Title:** Biological and Pragmatic Interventions in Heart Failure: From Present to Future  
**Session Time:** 8:00 AM – 9:15 AM CT  
**Presentation Time:** 8:24 AM – 8:32 AM CT  
**Location:** 211-213

#### Moderated Poster Presentations

**Title:** Improvement in Echocardiographic Measures of Diastolic Function Reflects Improved Exercise Performance in Obstructive Hypertrophic Cardiomyopathy: Insights From the SEQUOIA-HCM Trial  
**Presenter:** Henri Lu, M.D., Brigham and Women's Hospital, Harvard Medical School  
**Date:** November 8, 2025  
**Session Title:** Beyond the Usual Suspects: Imaging Insights in HCM and Rare Cardiomyopathies  
**Session Time:** 9:15 AM – 10:30 AM CT  
**Poster Presentation Time:** 9:43 AM – 9:48 AM CT  
**Location:** Clinical Science Zone 1, Moderated Digital Poster 7

**Title:** *Aficamten* is Safe and Effective in oHCM with Comorbidities Obesity, Hypertension, and Diabetes: a SEQUOIA-HCM Sub-study  
**Presenter:** Matthew M. Y. Lee, Ph.D., MBChB, School of Cardiovascular and Metabolic Health,

University of Glasgow

**Date:** November 8, 2025

**Session Title:** Targeting the Thickened Heart: Advances in Hypertrophic Cardiomyopathy Therapy

**Session Time:** 10:45 AM – 11:55 AM CT

**Poster Presentation Time:** 11:13 AM – 11:18 AM CT

**Location:** Clinical Science Zone 2, Moderated Digital Poster 24

**Title:** Effect of *Aficamten* in Women Compared with Men with Obstructive Hypertrophic Cardiomyopathy

**Presenter:** Xiaowen Wang, M.D., MPH, Brigham and Women's Hospital, Harvard Medical School

**Date:** November 8, 2025

**Session Title:** Heart Failure and Cardiomyopathy: From Bench to Bedside

**Session Time:** 3:15 PM – 4:25 PM CT

**Poster Presentation Time:** 4:04 PM – 4:09 PM CT

**Location:** Clinical Science Zone 2, Moderated Digital Poster 22

**Title:** Chronic *Aficamten* Treatment Results in Sustained Favorable Cardiac Remodeling in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights From the FOREST-HCM Trial

**Presenter:** Sheila M. Hegde, M.D., MPH, UT Southwestern Medical Center and Brigham and Women's Hospital, Harvard Medical School

**Date:** November 8, 2025

**Session Title:** Imaging Insights from Multicenter Clinical Trials

**Session Time:** 10:45 AM – 11:55 AM CT

**Poster Presentation Time:** 10:45 AM – 10:50 AM CT

**Location:** Clinical Science Zone 1, Moderated Digital Poster 8

**Title:** Lactate Dehydrogenase and Clinical Outcomes in Patients with Heart Failure and Reduced Ejection Fraction: Insights From the GALACTIC-HF Trial

**Presenter:** Ryohei Ono, M.D., Ph.D., British Heart Foundation Cardiovascular Research Centre, University of Glasgow

**Date:** November 9, 2025

**Session Title:** Drivers of Heart Failure: Environmental and Behavioral Factors

**Session Time:** 9:15 AM – 10:30 AM CT

**Poster Presentation Time:** 10:04 AM – 10:09 AM CT

**Location:** Clinical Science Zone 2, Moderated Digital Poster 18

## Poster Presentations

**Title:** Semiquantitative Urine Dipstick Protein Assessments Predict Clinical Outcomes in Patients with Heart Failure and Reduced Ejection Fraction: Insights From the GALACTIC-HF Trial

**Presenter:** Ryohei Ono, M.D., Ph.D., British Heart Foundation Cardiovascular Research Centre, University of Glasgow

**Date:** November 8, 2025

**Session Title:** Biomarkers in HF: Past, Present, and Future

**Session Time:** 2:30 PM – 3:30 PM CT

**Location:** Clinical Science Zone 2

## About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics is readying

for potential regulatory approvals and commercialization of *aficamten*, an investigational cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). *Aficamten* is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. In addition, Cytokinetics is developing *omecamtiv mecarbil*, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), *ulacamten*, a cardiac myosin inhibitor with a mechanism of action distinct from *aficamten*, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.

For additional information about Cytokinetics, visit [www.cytokinetics.com](http://www.cytokinetics.com) and follow us on [X](#), [LinkedIn](#), [Facebook](#) and [YouTube](#).

### Disclaimer

*Aficamten*, *omecamtiv mecarbil*, *ulacamten* and CK-089 are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency.

### Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to any of our clinical trials, statements relating to the potential benefits of *aficamten* or any of our other drug candidates. Cytokinetics' research and development activities; the design, timing, results, significance and utility of preclinical and clinical results; and the properties and potential benefits of Cytokinetics' other drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics' drug candidates that could slow or prevent clinical development or product approval; Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics' ability to conduct clinical trials; Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; standards of care may change, rendering Cytokinetics' drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics' drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.

CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Contact:  
Cytokinetics  
Diane Weiser  
Senior Vice President, Corporate Affairs  
(415) 290-7757

Source: Cytokinetics, Incorporated